Skip to main content

Table 1 Patients' characteristics

From: Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy

Patient Baseline evaluation After treatment
  ER, % PgR, % HER2, % (score) First assessment Time A Chemotherapy Time B Second assessment ER, % PgR, % HER2, % (score) HT Clinical response
1 0 0 80 (3+) Skin 20 Paclitaxel 9 Skin 10 0 70 (3+) No PR
2 0 0 70 (3+) Pleura 87 Paclitaxel 11 Pleura 0 0 75 (3+) No SD
3 0 0 90 (3+) Skin 8 Nonea 4 Skin 0 0 90 (3+) No PR
4 0 0 40 (3+) Skin 31 Paclitaxel 9 Skin 0 0 90 (3+) No PD
5 0 0 90 (3+) Liver 5 Nonea 12 Ovary 50 40 80 (3+) Yes PD
6 0 0 95 (3+) Breast 2 Paclitaxel 37 Breast 20 0 90 (3+) Yes PR
7 0 0 80 (3+) Skin 64 Nonea 4 Skin 0 0 95 (3+) No PR
8 0 0 90 (3+) Lung 2 Paclitaxel 4 Skin 0 0 90 (3+) No SD
9 0 0 80 (3+) Skin 51 Paclitaxel 22 Skin 0 0 40 (2+) No PR
10 0 0 90 (3+) Skin 17 Vinorelbine 3 Skin 0 0 90 (3+) No PR
  1. The table shows the evaluation of patients' characteristics at baseline with the site of disease at which the biological characteristics were evaluated, and after treatment with trastuzumab with the site of disease at which the biological characteristics were reassessed. ER, estrogen receptor; first assessment, site of disease where ER, PgR and HER2 were evaluated at baseline; HT, hormonal treatment; PgR, progesterone receptor; second assessment, site of disease where ER, PgR and HER2 were reassessed; time A, time elapsed between first assessment and treatment start (weeks); time B, time elapsed between trastuzumab start and second assessment (weeks). PD, progressive disease. SD, stable disease. PR, partial response.
  2. aPaclitaxel was introduced after progression to trastuzumab alone.